Evidence map›Paper›PMID 26558529›Full record

ArticleScientific reports2015

Single cell analysis of cancer cells using an improved RT-MLPA method has potential for cancer diagnosis and monitoring.

L Kvastad, B Werne Solnestam, E Johansson, A O Nygren, N Laddach, P Sahlén, S Vickovic, Schirmer C Bendigtsen, M Aaserud, L Floer and 5 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Impact of anthracycline-based chemotherapy on RB1 gene methylation in peripheral blood leukocytes and biomarkers of oxidative stress and inflammation in sarcoma patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 5 countries.

L KvastadScience for Life Laboratory, School of Biotechnology, Royal Institute of Technology (KTH), SE-171 65, Solna, Sweden.
B Werne SolnestamScience for Life Laboratory, School of Biotechnology, Royal Institute of Technology (KTH), SE-171 65, Solna, Sweden.
E JohanssonScience for Life Laboratory, School of Biotechnology, Royal Institute of Technology (KTH), SE-171 65, Solna, Sweden.
A O NygrenMRC-Holland, Amsterdam, The Netherlands.
N LaddachMRC-Holland, Amsterdam, The Netherlands.
P SahlénScience for Life Laboratory, School of Biotechnology, Royal Institute of Technology (KTH), SE-171 65, Solna, Sweden.
S VickovicScience for Life Laboratory, School of Biotechnology, Royal Institute of Technology (KTH), SE-171 65, Solna, Sweden.
Schirmer C BendigtsenPathology Dept, Radiumhospitalet, Oslo University Hospital, Oslo, Norway.
M AaserudPathology Dept, Radiumhospitalet, Oslo University Hospital, Oslo, Norway.
L FloerPathology Dept, Radiumhospitalet, Oslo University Hospital, Oslo, Norway.
E BorgenPathology Dept, Radiumhospitalet, Oslo University Hospital, Oslo, Norway.
C SchwindFraunhofer ICT-IMM, Mainz, Germany.
R HimmelreichFraunhofer ICT-IMM, Mainz, Germany.
D LattaFraunhofer ICT-IMM, Mainz, Germany.
J LundebergScience for Life Laboratory, School of Biotechnology, Royal Institute of Technology (KTH), SE-171 65, Solna, Sweden.
KTH Royal Institute of Technology · SEOslo University Hospital · NOFraunhofer Institute for Chemical Technology · DEScience for Life Laboratory · SEAsana Biosciences (United States) · USFraunhofer Institute for Microengineering and Microsystems · DEMRC Holland (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single cell analysis techniques have great potential in the cancer genomics field. The detection and characterization of circulating tumour cells are important for identifying metastatic disease at an early stage and monitoring it. This protocol is based on transcript profiling using Reverse Transcriptase Multiplex Ligation-dependent Probe Amplification (RT-MLPA), which is a specific method for simultaneous detection of multiple mRNA transcripts. Because of the small amount of (circulating) tumour cells, a pre-amplification reaction is performed after reverse transcription to generate a sufficient number of target molecules for the MLPA reaction. We designed a highly sensitive method for detecting and quantifying a panel of seven genes whose expression patterns are associated with breast cancer, and optimized the method for single cell analysis. For detection we used a fluorescence-dependent semi-quantitative method involving hybridization of unique barcodes to an array. We evaluated the method using three human breast cancer cell lines and identified specific gene expression profiles for each line. Furthermore, we applied the method to single cells and confirmed the heterogeneity of a cell population. Successful gene detection from cancer cells in human blood from metastatic breast cancer patients supports the use of RT-MLPA as a diagnostic tool for cancer genomics.

Indexed as

Case-Control StudiesCell Line, TumorGene Expression ProfilingHumansMultiplex Polymerase Chain ReactionNeoplasmsNeoplastic Cells, CirculatingReproducibility of ResultsSensitivity and SpecificitySequence Analysis, RNASingle-Cell Analysis

Identifiers

PMID26558529
PMCPMC4642268
OpenAlexW95518212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.